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Abstract
Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome defined by clinical and laboratory criteria. Current criteria were created to identify patients with familial hemophagocytic lmyphohistiocytosis in immediate need of immunosuppressive therapy.
However, these criteria also identify patients with infection-associated hemophagocytic inflammatory states lacking genetic defects typically predisposing to hemophagocytic lymphohistiocytosis. This includes patients with primary immunodeficiencies, in whom pathogenesis of the inflammatory syndrome may be distinctive and aggressive immunosuppression contraindicated. To better characterize hemophagocytic inflammation associated with immunodeficiencies, we combined an international survey with a literature search and identified 63 patients with primary immunodeficiencies other than cytotoxicity defects or X-linked lymphoproliferative disorders, presenting with conditions fulfilling current criteria for hemophagocytic lymphohistiocytosis. Twelve patients had severe combined immunodeficiency with <100/µl T-cells, 18 had partial T-cell deficiencies; episodes of hemophagocytic lymphohistiocytosis were mostly associated with viral infections. Twenty-two patients had chronic granulomatous disease with hemophagocytic episodes mainly associated with bacterial infections. Compared to patients with cytotoxicity defects, patients with T-cell deficiencies had lower soluble CD25 and higher ferritin. Other criteria for hemophagocytoc lymphohistiocytosis were not discriminative. Thus, (i) a hemophagocytic inflammatory syndrome fulfilling criteria for hemophagocytic lymphohistiocytosis can be the initial manifestation of primary immunodeficiencies. (ii) this syndrome can develop despite severe deficiency of T-and NK-cells, implicating that pathophysiology is distinct and not appropriately described as "Lympho"-Histiocytosis in these patients (iii) current criteria for hemophagocytoc lymphohistiocytosis are insufficient to differentiate hemophagocytic inflammatory syndromes with different pathogenesis. This is important because of implications for therapy, in particular for protocols targeting T-cells. One well-defined group of patients in whom the HLH syndrome has been described, are patients with primary immunodeficiencies (PID) other than FHL or XLP. Single cases or small case series of the HLH syndrome have been reported in a variety of PIDs, and the clinical presentation of some of these cases has recently been summarized. 11 However, a multicenter systematic analysis of the clinical and laboratory features of the HLH syndrome in these patients in comparison to HLH associated with defects in lymphocyte cytotoxicity has not been performed. We reasoned that such an analysis might offer the opportunity to identify parameters for differential diagnosis, facilitating early identification of patients with hemophagocytic inflammatory disease in which aggressive immunosuppressive therapy may be contraindicated. Furthermore, since primary immunodeficiencies provide an excellent possibility to study the role of constitutional immunological abnormalities in immunopathological conditions, we expected to gain some insights relevant to the pathogenesis of the HLH syndrome.
Introduction

Methods
Patient recruitment
To Patients were included if they fulfilled the following criteria: (i) genetic or clinical diagnosis of a defined PID as classified by the international union of immunological societies expert committee for primary immunodeficiency (IUIS) except for genetic defects in cytotoxicity, XLP1 or XLP2. 12 (ii) Fulfillment of at least five out of eight diagnostic criteria for HLH according to the HLH-2004 criteria. 7 These include: 1. fever, 2. splenomegaly, 3. cytopenia of
hypofibrinogenemia (≤1.5 g/L) or hypertriglyceridemia (≥265 mg/dL), 5. hyperferritinemia (≥500 ng/mL), 6. increased level of soluble CD25 (sCD25, ≥ 2400 U/mL), 7. evidence of hemophagocytosis, and 8. decreased or absent NK-cell cytotoxicity. From all patients, we recorded the underlying immunodeficiency diagnosis, the individual diagnostic criteria for HLH, associated infections, treatment and outcome of the HLH episode and whether or not HLH developed at/before or after PID diagnosis.
Control groups
Laboratory values of these patients were compared to those observed in a cohort of patients with active "primary" HLH (FHL 2-5; n=90) and a cohort of patients with infection-associated 
Statistical analysis
Statistical analysis was performed with the GraphPad InStat software version 6.05. First we calculated the natural logarithms of the mean of sCD25, ferritin, fibrinogen, and triglycerides. Differences between group means were then evaluated with a one-way analysis of variance with post-hoc Tukey test. Differences were considered significant at p<0.05.
Ethics
The study was approved by the ethics committee of the Albert-Ludwigs-Universität Freiburg (AK28/14) and conducted according to the Declaration of Helsinki.
Results
Patient cohort and sequence of diagnosis
We identified 28 patients with primary immunodeficiencies other than defects in cytotoxicity or XLP fulfilling the HLH-2004 diagnostic criteria through the survey and found 30 publications describing another 35 cases (Table 1) . Six of the 18 cases recently summarized by Faitelson 11 were not included in this analysis because of incomplete information on our inclusion criteria as were 10 cases identified by either the survey or the literature review. In total, we identified 63 patients with PID and an HLH syndrome. Median age at diagnosis of the HLH syndrome was 1.5 years (range 0.13-34 years). Notably, an HLH syndrome was the initial presentation leading to diagnosis of the underlying PID in 36 patients, whereas 25 patients developed HLH after the PID diagnosis had been established;
for two patients this information was not available.
Spectrum of primary immunodeficiencies presenting with an HLH syndrome
Two main groups of PID represented more than 80% of patients. Thirty patients had combined immunodeficiencies (CID). More specifically, twelve patients had SCID with a variety of molecular causes (Table 1) . Interestingly, in 9/12 of these patients, the HLH syndrome developed in the first months of life, at or before the diagnosis of the immunodeficiency. Eighteen patients had other well-characterized combined immunodeficiencies affecting T cell development or function, including "atypical" SCID 44 with significant numbers of autologous T cells (n=2), 22q11 deletion syndrome (n=4), WiskottAldrich syndrome (n=4), ataxia telangiectasia (n=1) and dyskeratosis congenita (n=1). Two patients had CD27 deficiency and one had ITK deficiency, conditions that have previously been associated with poor control of EBV infection (Table 1) . 45, 46 The second main group consisted of 22 patients with chronic granulomatous disease (CGD) ( Table 1) . Most of these patients presented with an HLH syndrome beyond the first year of life, some in adulthood. In nine of the younger patients (<4 years), the HLH syndrome developed at or before the diagnosis of CGD. Only eleven patients had other PID, including antibody deficiencies (n=2), diseases of immune dysregulation (n=2), other congenital defects of phagocytes (n=1), defects in innate immunity (n=2), or autoinflammatory disorders (n=4) ( Table 1) .
Infections associated with the HLH syndrome in PID patients
In 50/63 patients (79%), the HLH syndrome was associated with an infection. In SCID and CID patients, it was mainly associated with viral infections. Ten of 30 (33%) patients had EBV infection, 7 had CMV infection, three had infections with adenovirus and two had infections with other gastrointestinal or respiratory viruses. In contrast, in only two of 22 (9%) of CGD patients, the HLH syndrome was associated with a viral infection and in both cases an additional bacterial infection was diagnosed. The main infectious agents in the group of CGD patients were Burkholderia cepacia (n=7), Leishmania spp. (n=6), and fungi (n=4). In the group of eleven patients with other PID, the HLH syndrome was associated with a viral infection in three and a bacterial infection in two patients (table 1) .
Lymphocyte compartment in SCID patients
Since in familial HLH (FHL), activated T cells and possibly NK cells are regarded as major effectors in disease pathogenesis, 1, 3 we had a closer look at the lymphocyte compartment in the SCID patients. Interestingly, all SCID patients had fewer than 100 T cells/µl (including 9
patients with less than 20 T cells/µl) ( Table 2 ). Four patients had been analyzed for maternal T cells, which were detected at low numbers in 2 of them. Three patients also had 10 or fewer NK cells/µl. The number of B cells was more variable.
Diagnostic HLH parameters in PID patients presenting with the HLH syndrome
Information on all eight HLH-2004 diagnostic criteria was only available for 7 patients, while 7 criteria were reported in additional 15 patients. These patients usually lacked information on sCD25 (reported in 23/63 patients, 36%) or NK cell cytotoxicity (reported in 19/63 patients, 30%). On the other hand, all patients fulfilled at least 5 diagnostic criteria. In 36 patients (57%), all of the 5-8 reported criteria were positive. When looking at individual criteria, no particular pattern emerged that would be characteristic for PID or PID subgroups. Of the patients for which information on these criterion was available, ninety-eight percent had fever, 91% had splenomegaly, 91% had cytopenias, 80% had elevated triglycerides, 75%
had low fibrinogen, 100% had elevated ferritin, 82% had elevated sCD25 and 63% had low or absent NK cell cytotoxicity.
We then quantitatively compared the laboratory values of patients with T cell deficiencies and CGD to those obtained in a cohort with FHL (n=90) and a cohort of patients with infectionassociated HLH without known underlying hereditary disease (I-HLH, n=40). The most significant differences were observed in the serum concentrations of soluble interleukin-2 receptor (sCD25) ( Figure 1A , Table 3 ). Patients with T cell deficiencies had significantly lower values than those observed in patients with FHL (mean: T cell deficiencies: 5290 U/ml, FHL: 23074 U/ml; p<0.0001). Notably, levels were also lower in patients with I-HLH than in patients with FHL. In contrast, the concentrations of ferritin were higher in the patients with T cell deficiencies than in the other three patient groups, but only significantly higher when compared to FHL patients (p<0.05; mean: T cell deficiencies: 64808 ng/ml, FHL: 10154 ng/ml, I-HLH: 8359 ng/ml, CGD 8819 ng/ml; Figure 1B ). These differences were even more obvious, when the ratio of ferritin/sCD25 was determined, which was significantly higher in patients with T cell deficiency compared to FHL, I-HLH, and CGD patients (mean: T cell deficiencies: 14.18, FHL: 0.37, I-HLH: 0.48, CGD: 0.90; Figure 1C ; see figure for p-values).
Apart from a significant difference in fibrinogen levels between FHL and I-HLH patients, no relevant differences were observed in the other HLH-defining parameters (mean FHL: 1.218 g/l, I-HLH: 1.869 g/l; p<0.05; Figure 2 ).
Treatment and outcome
The patients received a wide range of HLH-directed treatment regimens, including corticosteroids alone or in combination with IVIG, cyclosporine or rituximab (Table 1) .
Etoposide based therapy was given to 14 patients. This included 10 patients with T cell deficiencies, 6 of whom received their PID diagnosis during or after the episode of HLH syndrome. Only one patient with CGD received etoposide based therapy. Thirty-nine patients (65%) of 60 patients with reported outcome survived the HLH syndrome. Of note, only 4/12 SCID patients and 9/18 patients with CID and reported outcome survived, which contrasted with 20/22 CGD patients.
Discussion
This study identified 63 patients with PID other than genetic disorders of cytotoxicity or XLP, who fulfilled the current clinical criteria for HLH. In 36 of them, this HLH syndrome was the initial manifestation before or at the diagnosis of PID. Primary immunodeficiencies other than disorders of cytotoxicity or XLP are therefore a relevant differential diagnosis in patients presenting with the clinical picture of the HLH syndrome.
While many PIDs may predispose to an infection-triggered HLH syndrome, this was largely restricted to two groups in this cohort: patients with T cell deficiencies, who are susceptible to a broad range of infections, virus infections in particular, and patients with chronic granulomatous disease, who are susceptible to a smaller spectrum of bacterial and opportunistic, but not to viral infections. Infections associated with the HLH syndrome in PID patients reflected this specific susceptibility, compatible with the notion that uncontrolled pathogen replication is a major risk factor for this hyperinflammatory syndrome. However, while the HLH syndrome was observed in a relevant number of CGD patients, it was not reported in other congenital defects in phagocytes and only rarely in other defects in innate immunity. It is therefore tempting to hypothesize that the HLH syndrome in CGD may not only reflect impaired infection control, but also a genetic predisposition to hyperinflammation.
Colitis and other inflammatory organ pathology associated with granuloma formation are well-known complications in this disease, 47 which were recently linked to autophagic dysfunction 48 . This apparent association of impaired autophagy to the HLH syndrome therefore warrants future investigation. It should be noted that the design of our study did not allow us to exclude a potential contribution of monoallelic mutations or polymorphisms in FHL associated genes to the manifestation of HLH in all patients. Nevertheless, at least seven patients were tested for all known genes associated with FHL and in a number of other patients individual genes have been sequenced without detection of relevant mutations or polymorphisms such as perforin A91V.
An imbalance between virus control and immune activation is thought to be an important determinant for the HLH syndrome associated with viral infections (such as EBV) and in a proportion of patients with FHL. This is supported by evidence from mouse models. 3, 49 In these models, hyperactive T cells are a key factor in disease pathogenesis. 2, 50 It was therefore surprising that, paradoxically, a significant number of patients with T cell deficiencies, including several patients without detectable circulating T cells, developed the HLH syndrome. Notably, at least 3 T cell deficient X-SCID patients also had ≤ 10/µl NK cells, rendering it unlikely that hyperactivated NK cells replaced T cells as a pathogenic factor in these cases. This is further supported by a significantly lower level of sCD25 in this patient group compared to patients with FHL or I-HLH. These observations suggests that the HLH syndrome can develop despite the severe deficiency of T and NK cells, two main effectors implicated in "primary" HLH. Due to this absence of T and NK cells, the term hemophagocytic "lympho" histiocytosis appears inappropriate to describe the "HLH-like" disease in SCID patients. It seems likely that in these patients activation of macrophages and the associated cytokine release proceed independent of lymphocytes. Therefore, the term "hemophagocytic inflammatory syndrome" (HIS) may better describe this condition. Although not addressed in this study, it is possible that such a distinction may also be relevant for some other disease states currently classified as "secondary" HLH. what is usually observed in "primary" or infection-associated "secondary" HLH. It should be stated that in most PID patients summarized in this study, not all 8 criteria were documented.
However, sCD25 is frequently also not determined in many patients with familial HLH and in most centers NK cell cytotoxicity has been replaced by intracellular protein and degranulation studies. 51 The only notable difference between the groups was the relatively low sCD25 levels and high ferritin levels in most patients with T cell deficiencies. This most likely reflects the lack of T cells in SCID and the low T cell counts and/or impaired T cell function in CID patients. Furthermore, the ratio of ferritin to sCD25 heightened these differences and appears to be a useful measure, as has previously been suggested in lymphoma-associated HLH. 52 Our (admittedly limited) data suggest that a ferritin:sCD25 ratio of >3 should be viewed as suggestive of SCID/CID in an infant with the HLH syndrome. Because current understanding of HLH pathogenesis suggests that "overactivated" T cells exuberantly recruit innate effectors (macrophages) to drive HLH disease manifestations, 3,53 these findings suggest that uncontrolled viral infections in the context of SCID/CID may circumvent typical HLH pathogenesis. It remains to be shown whether such an alternative pathophysiology may also be relevant for some cases of infection-associated or rheumatologic "secondary"
HLH in apparently immunocompetent individuals. In this context it is noteworthy that sCD25 levels were also significantly lower in patients with infection-associated "secondary" HLH than in patients with FHL, though this may simply illustrate the propensity towards T cell 'overactivation' in individuals with defective cytotoxic function.
Disease classification should be based on pathophysiological knowledge with the goal to facilitate the best treatment decision for affected patients. The observations of this study further illustrate that the current diagnostic HLH criteria as defined by the HLH-2004 protocol describe a common clinical and biological endpoint resulting from different conditions and pathways of pathogenesis. We think that there are good arguments to reserve the term hemophagocytic "lympho" histiocytosis (HLH) to disease states that are associated with a predominantly T cell mediated immunopathogenesis, including "primary" HLH and some cases of infection-associated "secondary" HLH. In these cases, etoposide-based protocols or T cell directed immune therapy, e.g. based on ATG 9 or alemtuzumab, 54 are indicated and can be highly effective. On the contrary, strong immunosuppressive therapy may not always be appropriate and even harmful for other patient groups, especially patients with primary immunodeficiencies other than FHL or XLP. In this study, we propose the provisional term "hemophagocytic inflammatory syndrome" (HIS) to classify these patients, in whom the intensity of immunosuppressive treatment needs to be carefully adapted to the underlying immunodeficiency and ongoing infections.
HIS could be an umbrella term for different diseases currently referred to as "primary" or "secondary" forms of HLH or MAS. In this concept, HLH would be one form of HIS. We propose to maintain the term "hemophagocytic" despite the fact that not all patients fulfill this criterion (41/50 in our study) for the following reasons: 1. The probability to detect hemophagocytosis depends on the time point of the analysis, which is in many cases performed only once. 2. The element of activated phagocytes producing cytokines is likely to be essential for all forms of HIS. 3. Keeping this element will keep the term searchable in the literature and maintain awareness of physicians that this is a serious condition. 4. The term hyperinflammatory alone is poorly discriminative towards other inflammatory conditions. It is important to note that these considerations represent a suggestion and any change in nomenclature should be legitimated by the Histiocyte Society, that is currently engaged in revising the terminology for this group of diseases.
It is an obvious difficulty of current nomenclature that a single clinical scenario (e.g. EBV associated HLH in an infant) could exemplify HLH associated with a defect in lymphocyte cytotoxicity, a T cell driven "secondary" HLH, or a T/NK cell independent HIS in a SCID patient, each with a potentially different pathophysiology and a common phenotypic endpoint.
It is thus important to remember that the HLH syndrome itself never represents a complete diagnosis. It will be an important challenge to elaborate diagnostic criteria that can help to separate etiologically different conditions. The ratio of ferritin to sCD25 may represent one of them, but new biomarkers specifically reflecting the individual pathophysiological pathway leading to the inflammatory disease state of the HLH syndrome are needed. It will be of particular interest to evaluate whether markers of immune cell activation in addition to cytokine patterns may more specifically reflect disease pathogenesis. 
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